Bausch + Lomb appoints Karen Ling to Board of Directors; Richard De Schutter to retire
Bausch + Lomb, a global eyecare company, has announced the appointment of Karen Ling as one of the members of the Board of Directors, with immediate effect.
Joining the board, Karen will take over from the current director Richard De Schutter, who is soon retiring from the board. In this role, Karen brings around 25 years of experience encompassing human capital management, HR leadership, corporate governance, and shareholder engagement. She is currently serving as the Director and Chair of the Compensation and Human Capital Management Committee at iRhythm Technologies, and as a Member of the Advisory Committee at Galderma.
In her previous roles, Karen served TherapeuticsMD as the Director and Compensation Committee Chair, AIG as the Executive Vice President and CHRO, Allergan as the CHRO, Merck as the Senior VP of Human Resources, and Wyeth as the VP of Employee Benefits and Compensation. On the academic front, she holds a bachelor's degree in Arts from Yale University and a Doctor of Law (JD) from Boston University School of Law.
Welcoming Karen to the executive board, Brent Saunders, chairman, and CEO of Bausch + Lomb, said, "With her extensive industry leadership experience and time as a public company director, Karen brings significant human capital management, corporate governance, and shareholder engagement expertise to the organisation. We’re confident her perspectives will be highly additive in the boardroom as Bausch + Lomb continues its evolution.”
Extending wishes to outgoing director Richard, he added, “Since my return to the company, Richard has been a trusted advisor. I join the rest of the Board in thanking him for his service and wishing him well as he pursues his many other interests.”
You may also like:
Karen also expressed, “I have long admired Bausch + Lomb’s reputation in eye health and am excited to join such a dynamic and innovative organisation as it executes an ambitious global growth strategy. I look forward to helping the company deliver value for all stakeholders in 2024 and beyond.”
